Ideaya Biosciences (IDYA) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ideaya Biosciences is running a new study to test its drug IDE574 in adults with advanced solid tumors and certain breast cancers. The official goal is to track safety, how the drug moves and acts in the body, and early signs of benefit, both alone and with fulvestrant, which matters because it targets hard to treat cancers where new options are limited.
The study tests IDE574, a lab made pill that blocks two enzymes linked to tumor growth. It is used alone in several solid tumors and together with fulvestrant in ER+, HER2- breast cancer, aiming to improve control of disease that has stopped responding to current hormone drugs.
The trial is interventional and early stage, combining phase 1 and phase 2 work in one plan. Patients are assigned to specific dosing groups rather than randomized, there is no placebo, and both doctors and participants know what they receive, with the main goal to treat cancer while defining safe and active doses.
The study began enrolling after April 2026, when it was first submitted to regulators, and focuses first on dose finding and early efficacy signals. The latest update on May 18, 2026 signals that the protocol is active, with primary and final completion dates still ahead and likely to shift as the company refines the trial.
For investors, this update highlights an early but strategic asset in Ideaya’s pipeline that could expand its reach beyond current DNA damage focused programs. Positive safety and activity data in ER+, HER2- breast cancer could lift IDYA shares, but timelines are long and competition from large oncology players means any readthrough should be viewed as optionality rather than near term revenue.
The study remains ongoing and recently updated, with further details and any future changes available on the ClinicalTrials.gov portal.
To learn more about IDYA’s potential, visit the Ideaya Biosciences drug pipeline page.